Welcome to our dedicated page for Natera news (Ticker: NTRA), a resource for investors and traders seeking the latest updates and insights on Natera stock.
Natera, Inc. develops and commercializes cell-free DNA and genetic testing for oncology, women’s health and organ health. Company updates commonly cover financial results, revenue trends, laboratory operations and publications supporting tests such as Signatera, Prospera, Panorama and Horizon.
Recurring news also includes oncology molecular residual disease applications, clinical evidence presented at medical meetings, transplant rejection surveillance data, collaborations using Natera assays in drug trials, and patent or litigation developments tied to its MRD technology. The company reports through CLIA-certified and CAP-accredited laboratory operations and through Foresight Diagnostics, its subsidiary.
Natera (NASDAQ:NTRA) announced an enhanced Panorama NIPT powered by SNP-informed deep sequencing, aimed at improving performance in low fetal fraction samples.
A prospective, blinded study in 3,323 patients, including 242 low fetal fraction or previously no-call samples, showed 100% sensitivity for trisomy 21 and 13, 93.3% for trisomy 18, and a reduced no-call rate of 0.5%, with all outcomes confirmed by diagnostic genetic testing.
Natera (NASDAQ:NTRA) will present 35 oncology studies, including 3 oral talks, at the 2026 ASCO meeting in Chicago.
Data feature Signatera-based MRD testing in colorectal cancer, a large pan-cancer meta-analysis, ultrasensitive phased variant technology across solid and blood cancers, plus new real-world evidence and an Annotation digital platform.
Natera (NASDAQ:NTRA) announced a major expansion at its North Austin headquarters, adding a dedicated sequencing facility and new lab space to support rapid growth.
The facility is expected to have the largest sequencing capacity in the world, meeting rising demand, especially in oncology, where testing volumes grew over 54% year-over-year in Q1 2026.
Natera’s Signatera test is used by more than 50% of U.S. oncologists, and Signatera CDx recently became the first FDA-approved companion diagnostic in molecular residual disease testing. The expansion is expected to create up to 400 new jobs across professional, laboratory, and operational roles while supporting hundreds of ongoing clinical trials and research collaborations.
Natera (NASDAQ:NTRA) reported that the EXPAND clinical trial of its Fetal Focus™ single-gene noninvasive prenatal test (NIPT) has enrolled over 2,000 patients, more than doubling enrollment in the past 12 months.
EXPAND is a prospective, blinded, multi-site study assessing Fetal Focus, which evaluates 21 genes linked to serious, early-onset conditions and uses LinkedSNP™ technology. Early EXPAND data showed strong clinical performance and accurate detection in 5 of 5 difficult homozygous cases.
Natera (NASDAQ:NTRA) announced FDA approval of Signatera CDx as a companion diagnostic for adjuvant atezolizumab (Tecentriq) immunotherapy in muscle-invasive bladder cancer (MIBC). This is the first FDA-approved blood-based MRD companion diagnostic.
According to Natera, IMvigor011 Phase III data showed MRD-positive patients on immunotherapy had improved DFS and OS, while MRD-negative patients achieved 97% 2-year OS without adjuvant therapy. Signatera is supported by 185+ publications and Medicare coverage across multiple cancer types.
Natera (NASDAQ: NTRA) reported Q1 2026 results: $696.6M revenue, up 38.8% year-over-year; processed 1,013,600 tests (up 18.5%); gross margin of 64.7%. Oncology tests rose 54.4% to 258,900. Net loss was $85.1M (−$0.60/share). Company raised 2026 revenue guidance to $2.74B–$2.82B and expects positive net cash inflow.
Natera (NASDAQ: NTRA) will release results for its first quarter ended March 31, 2026, after market close on May 7, 2026. A conference call and webcast will follow at 1:30 p.m. PT (4:30 p.m. ET), with replay available at the company's investor site.
Dial-in, conference ID and webcast links will be provided for investors and analysts to access the live presentation and Q&A.
Natera (NASDAQ: NTRA) will feature Prospera in 17 abstracts (six oral) at ISHLT 2026, highlighting heart and lung transplant applications. Key findings cite Prospera’s ability to predict 1-year adverse outcomes, influence clinical decisions in >30% of cases, reduce false positives with DQS, and detect CLAD, infection, and reflux-related injury.
Natera highlighted Allogene Therapeutics' interim futility analysis from the ALPHA3 trial (ALLO) on April 13, 2026. The analysis reported 58.3% MRD clearance with cema-cel and a median 97.7% ctDNA decrease at Day 45 versus a 26.6% median increase in observation.
The trial uses Natera's CLARITY MRD assay to randomize MRD-positive LBCL patients to cema-cel or observation; results are interim and final clinical outcomes remain pending.
Natera (NASDAQ: NTRA) said a Delaware federal judge on April 6, 2026 awarded Natera a 30% ongoing royalty on post-injunction revenues from infringing MRD-related product sales that fall within exceptions to a Nov 21, 2023 injunction.
The jury’s prior 20.5% effective royalty on pre-injunction revenues remains unchanged, and the court upheld validity of all three asserted MRD patents. Natera noted it holds over 650 issued or pending patents, including a portfolio of MRD patents.